Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Alnylam and The Medicines Co run PCSK9 race together through $205m alliance

This article was originally published in Scrip

Executive Summary

With an exclusive global alliance worth up to $205 million plus double-digit royalties to develop and commercialize Alnylam Pharmaceuticals' ALN-PCS, the RNAi specialist and The Medicines Company are in a crowded field of companies with hypercholesterolemia therapies targeting proprotein convertase subtilisin/kexin type 9 (PCSK9), which regulates low-density lipoprotein (LDL).

You may also be interested in...



The Medicines Co. CEO Timney On Selling Inclisiran And Why Big Pharma Is Still Interested In CV Disease

Mark Timney took over the helm at The Medicines Company in December with a singular focus: wrapping up the Phase III program for inclisiran and finding a buyer for the cholesterol-lowering drug. 

Finance Watch: 2021 Biopharma VC Funding Tops Full-Year 2020 Total

Private Company Edition: The industry raised $28bn in venture capital through the third quarter, breaking the record $27.4bn raised last year. Also, big pharmas backed a start-up lab in Israel, plus mega-rounds for CinCor Pharma ($143m) and Rectify Pharmaceuticals ($100m).

Biogen Seeking A Path Forward After Phase III Tofersen Study Fails In ALS

The drug showed favorable but not significant trends across secondary endpoints, and greater efficacy in slower-progressing patients and those treated earlier in the disease, in a small subpopulation.

Topics

Related Companies

UsernamePublicRestriction

Register

SC020289

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel